Abstract Blinding ocular herpetic disease in humans is due to herpes simplex virus type 1 (HSV-1) reactivations from latency, rather than to primary acute infection. The cellular and molecular immune mechanisms that control the HSV-1 latency-reactivation cycle remain to be fully elucidated. The aim of this study was to determine if reactivation of the HSV-1 latency-associated transcript (LAT) deletion mutant (dLAT2903) was impaired in this model, as it is in the rabbit model of induced and spontaneous reactivation and in the trigeminal ganglia (TG) explant-induced reactivation model in mice. The eyes of mice latently infected with wild-type HSV-1 strain McKrae (LAT (+) virus) or dLAT2903 (LAT (−) virus) were irradiated with UV-B, and reactivation was determined. We found that compared to LAT (−) virus, LAT (+) virus reactivated at a higher rate as determined by shedding of virus in tears on days 3 to 7 after UV-B treatment. Thus, the UV-Binduced reactivation mouse model of HSV-1 appears to be a useful small animal model for studying the mechanisms involved in how LAT enhances the HSV-1 reactivation phenotype. The utility of the model for investigating the immune evasion mechanisms regulating the HSV-1 latency/ reactivation cycle and for testing the protective efficacy of candidate therapeutic vaccines and drugs is discussed.
Introduction
Following primary infection at the eye, herpes simplex virus (HSV-1) replicates and travels up innervating neuronal axons to the trigeminal ganglia (TG) where it establishes a lifelong latent infection in sensory neurons. Herpes simplex virus (HSV-1) stromal keratitis (HSK) is a leading cause of corneal blindness in the USA (Smith et al. 1980) . HSK is an immunopathological process that is triggered by sporadic reactivation of HSV-1 from a latent state in sensory neurons, transport down neuronal axons, and shedding in tears (Chentoufi and BenMohamed 2012; Meyers 1975; Stuart et al. 2004 ). This leads to recurrent bouts of inflammation and progressive corneal scarring (Nesburn 1983) . However, the viral/host factors involved, and the underlying innate and adaptive immune mechanisms and their kinetics, remain to be fully elucidated. Major symptoms of recurrent herpes disease in the eye include clouding of the cornea and neovascularization, both of which can impair vision and lead to loss of sight. Over 400,000 people in the USA have a history of recurrent herpetic ocular disease (Farooq and Shukla 2012; Xu et al. 2002) . Estimates are that up to 90 % (Farooq and Shukla 2012; Kaufman et al. 2005; Xu et al. 2006 ) of adults in the US harbor latent HSV-1, making them susceptible to developing recurrent HSK (Kumaraguru et al. 1999; Rowe et al. 2013 ).
The HSV-1 latency-associated transcript gene (LAT) is expressed during latency (Rock et al. 1987; Spivack and Fraser 1987; Stevens et al. 1987; Stroop et al. 1984) and is the only viral gene that is consistently detected as being abundantly transcribed at this time (Rock et al. 1987) . The remaining 80 plus viral genes are shut down during latency. In mice, small amounts of mRNA from some of these genes are sometimes detected during latency. This is likely a result of sporadic abortive reactivations in single neurons, sometimes called Bmolecular reactivation^ (Feldman et al. 2002; Margolis et al. 2007) . Experiments in mice and rabbits have shown that LAT plays a critical role in enhancing the reactivation phenotype (Hill et al. 1990; Leib et al. 1989; Perng et al. 1994; Trousdale et al. 1991 ). This appears to be a function of LAT's antiapoptosis activity (Inman et al. 2001; Perng et al. 2000) , since wild-type levels of reactivation can be restored to a LAT (−) virus by inserting one of several different alternative antiapoptosis genes in place of LAT (Jin et al. 2008; Jin et al. 2007; Jin et al. 2005; Perng et al. 2002) . LAT may also contribute to latency/reactivation via numerous immune evasion mechanisms, such as its ability to directly or indirectly delay or interfere with interferon-gamma production (Peng et al. 2005) , protect against CD8 + T cell killing by blocking granzyme B-induced apoptosis (Jiang et al. 2011) , promote exhaustion of CD8 + T cells (Allen et al. 2011; Chentoufi et al. 2011) , and increase HVEM expression (Allen et al. 2014) (herpes virus entry mediator, a member of the tumor necrosis family) which can act as a switch to decrease T cell function.
Mouse studies of HSV-1 reactivation from latency have been limited by the fact that spontaneous reactivation of HSV-1 accompanied by return of the reactivated virus to the eye either does not occur or occurs at a rate too low for study (Feldman et al. 2002; Gebhardt and Halford 2005) . Thus, most HSV-1 reactivation studies in mice have been done ex vivo using the trigeminal ganglia (TG) explant-induced reactivation model (Deshmane et al. 1993; Devi-Rao et al. 1994; Leib et al. 1989; Perng et al. 2001; Spivack et al. 1995) . This is an ex vivo system in which reactivation is induced by sacrificing the mouse, removing the TGs, cutting them into small pieces, culturing the pieces in tissue culture media, and monitoring the media for the appearance of reactivated infectious virus. Whether the ex vivo TG explant-induced model of HSV-1 reactivation reliably mirrors the in vivo situation in humans is unclear. HSV-1 reactivation in mice can also be induced by other methods including hyperthermia, sodium butyrate, cyclophosphamide plus dexamethasone, cadmium, cellophane, xylene, retinoic acid, iontophoresis of epinephrine, dimethyl sulfoxide, and physical restraint (Blyth et al. 1980; Cook et al. 1991; Halford et al. 1996; Harbour et al. 1981; Higaki et al. 2003; Higaki et al. 2002; Hill et al. 1982; Himmelein et al. 2011; Neumann et al. 2007; Sawtell and Thompson 1992; Toma et al. 2008; Zlotnik et al. 1970) . A potential drawback of these models is that there are no reports of recurrent eye disease being induced. Thus, these models may not be optimal for the study of therapeutic interventions aimed at preventing recurrent HSK.
Fortunately, an in vivo HSV-1 reactivation model in mice in which significant recurrent corneal disease is induced has been developed (Laycock et al. 1991) . In this model, mice are ocularly infected with HSV-1 to establish cohorts of latently infected mice. The eyes of the latently infected mice are subsequently irradiated with UV-B light. This induces reactivation of the virus and its return to the eye, as determined by the detection of infectious HSV-1 in the tears of approximately 50 % of eyes between days 3 and 7 post UV-B exposure. Recurrent herpetic eye disease also occurs at high levels in this model. The use of this UV-B model appears to be mostly limited to the lab that developed this model and investigators from that lab (Keadle et al. , 1997 (Keadle et al. , 2002a (Keadle et al. , 2002b (Keadle et al. , 2005 (Keadle et al. , 2002c (Keadle et al. , 2001 (Keadle et al. , 2000 Laycock et al. 1991; Morris et al. 2012a; Stuart and Keadle 2012a; Stuart et al. 2008; Walker et al. 1998) . A recent video (Morris et al. 2012a ) demonstrating the UV-B model convinced us to attempt the model in our lab. We were particularly interested in determining if wildtype (LAT (+) ) virus would reactivate at a higher rate than LAT (−) virus following UV-B-induced reactivation, as is the case for spontaneous and in vivo induced reactivation in rabbits (Hill et al. 1990; Perng et al. 1994) , and for TG explantinduced reactivation (Leib et al. 1989 ) and heat stress-induced reactivation (Sawtell and Thompson 1992) in mice.
We report here that: (i) we were successful in performing the UV-B model of HSV-1-induced reactivation in latently infected mice and the results were consistent with those previously reported (Laycock et al. 1991; Morris et al. 2012a) , and (ii) compared to LAT (−) virus (dLAT2903), wild-type (LAT (+) ) HSV-1 reactivated at a higher rate in the UV-B mouse model, as determined by shedding of virus in tears on days 3 to 7 after UV-B treatment. The usefulness of the UV-B light mouse model in investigating the underlying LATmediate immune evasion mechanisms that regulate HSV-1 latency/reactivation and in testing the efficacy of candidate therapeutic vaccines and drugs is discussed.
Materials and methods
Cell lines Rabbit skin (RS) cells were maintained in Eagle's minimal essential medium (MEM) with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 % fetal bovine serum (Promega Scientific), penicillin (100 U/ml), and streptomycin (100 μg/ml) (Sigma, St. Louis, MO).
Viruses All viruses were triple plaque purified and passaged only two or three times in rabbit skin (RS) cells prior to use. LAT (+) wild-type (wt) HSV-1 strain McKrae is the parental virus for the LAT (−) mutant dLAT2903. Both viruses have been previously described (Perng et al. 1994 ).
Mice Eight-to 10-week-old female C57BL/6 mice (Jackson Labs) were used in all studies. All animal studies conform to the UC Irvine IACUC guidelines and the guidelines of the US National Institute of Health.
Infection of mice Ocular infection of mice was performed as described by (Morris et al. 2012a ) using 1×10 6 pfu of either LAT (+) McKrae or LAT (−) dLAT2903 per eye. Briefly, mice were anesthetized and corneas were scarified (i.e., the epithelium was lightly scratched) in a crosshatched pattern of four to five vertical and four to five horizontal scratches using a 25-gauge needle. Each mouse received an i.p. injection of 0.5 ml of pooled serum containing HSV-1-neutralizing antibodies with a 50 % plaque reduction neutralization titer of approximately 1:128. The serum we used differed from that previously used (Morris et al. 2012a ) as we used pooled serum from rabbits latently infected with HSV-1 instead of pooled human serum. In the pilot study (experiment 1 in Fig. 2 ), only the right eyes of mice were infected, consistent with the description of the UV-B mouse model (Morris et al. 2012a ). In experiment 2 in Figs. 2 and 3 and in the experiment shown in Fig. 4 , both eyes were infected.
UV-B irradiation of mouse eyes, monitoring shedding of reactivated HSV-1 in tears, and monitoring recurrent eye disease UV-B irradiation was done exactly as described (Morris et al. 2012a) , including using the same UV-B light source, except that in some experiments, both eyes were used. Briefly, anesthetized mice were placed on a TM20 ChromatoVu transilluminator (UVP, San Gabriel, CA), which emits UV-B at a peak wavelength of 302 nm. Each mouse was positioned on a piece of cardboard containing a hole that is the same size as the mouse's eye. This allowed just the eye to be irradiated by the UV-B source. Each eye was irradiated with 250 mJ of UV-B light cm 2 (approximately 1 min exposure on the transilluminator). On days 3, 4, 5, 6, and 7 post UV-B irradiation, eyes were swabbed and tear films plated on RS cells for detection of reactivated virus as we previously described for monitoring lytic virus replication in eyes of rabbits and mice and spontaneously reactivated virus in eyes of rabbits (Jin et al. 2005; Perng et al. 1994) . Recurrent eye disease was monitored at various times post UV-B irradiation as described (Morris et al. 2012a) .
Results
Inducing reactivation of HSV-1 latency by UV-B irradiation as judged by detection of infectious virus in tears of mice We first did a small pilot study using nine infected and two uninfected eyes following the published procedure (Morris et al. 2012a ) as closely as possible. An outline of the time course of the UV-B-induced reactivation experiments in this report is illustrated in Fig. 1 . As described in Materials and methods, nine C57BL/6 female mice were anesthetized. The right cornea of each mouse was lightly scarified and infected with 1×10
6 pfu/eye of the McKrae strain of HSV-1 as eye drops. Just prior to infection, each mouse received an i.p. injection of 0.5 ml of immune serum containing HSV-1-neutralizing antibody to partially protect against acute eye disease and death. Thirty days postinfection, the nine infected eyes were irradiated with 250 mJ of UV-B (302 nm). The right eyes of two naïve age-and sex-matched control mice were subjected to the same UV-B irradiation. The only known variance from the published procedure was that we used anti-HSV-1 pooled rabbit immune serum instead of pooled human immune serum to help protect the infected mice against the primary HSV-1 infection. Following UV-B irradiation, tear swabs were collected daily for 7 days and plated on indicator cells (RS cells) to detect the presence of infectious virus that had reactivated in the corresponding TG and returned to the eye. Figure 2a (Expt 1) shows the cumulative percent of eyes that had at least one virus-positive tear culture in this study. Infectious virus indicative of latent virus that reactivated in the corresponding TG and returned to the eye was detected in approximately 55 % of the eyes in this experiment. These results are similar to those previously reported (Laycock et al. 1991; Morris et al. 2012a ) and show that UV-B irradiation induces reactivation of HSV-1 that can be detected by shedding of virus in tears.
We also determined the cumulative number of viruspositive tear film cultures ( Fig. 2b; Expt 1 ). This takes into account multiple days on which an eye shed virus and is one of the standard analyses we perform when analyzing spontaneous reactivation in rabbit eyes (Perng et al. 1994) . Since in this, and subsequent experiments, we never detected virus in any mouse eye prior to day 3 post UV-B treatment or after day 7 post UV-B treatment, the total number of cultures used for these calculations excluded days 0, 1, and 2 and days 8 and later. The calculation was done as follows: [(number of viruspositive tear film cultures on that day+the number of positive cultures on all preceding days)/(total number of tear film cultures evaluated from day 3 to day 7)]×100 %. Thus, the denominator was 9 eyes×5 swabs (days 3, 4, 5, 6, 7) or 45.
To confirm the results in the pilot study and to determine if using both eyes rather than just one eye per mouse would produce similar results, both eyes from 10 mice (20 eyes/group) were either infected with wt McKrae or mock infected (naïve mice). All other manipulations were identical to those in the pilot study. The HSV-1 reactivation results are shown in Fig. 2a, b (Expt 2) . Both the cumulative percent of eyes shedding reactivated virus and the cumulative percent of virus-positive cultures were virtually identical to those in the smaller pilot study. These results confirmed that we were able to perform the mouse UV-B-induced reactivation model, as judged by induction of shedding virus in mouse tears.
Inducing recurrent eye disease using UV-B In addition to inducing shedding of virus in tears, the UV-B model is also reported to induce recurrent herpetic disease as judged by stromal clouding (Laycock et al. 1991; Morris et al. 2012a, b) . To confirm that we were also able to reproduce this result, corneal herpetic disease was determined in the eyes of the mice in experiment 2 before and after UV-B irradiation. One day prior to UV-B, all eyes in both groups were scored on a scale of 0 to 4 by examination under a dissecting microscope, as previously described (Morris et al. 2012a, b) . Five eyes had significant disease prior to UV-B irradiation. This was a result of the primary ocular infection. These eyes were removed from the study because the existing disease would make it impossible to score disease induced by UV-B reactivation of HSV-1. All 20 eyes in the control group were normal prior to UV-B. Following UV-B irradiation, the amount of disease in individual eyes was evaluated and scored on the days indicated in Fig. 3 , by an individual who was masked as to which group the eye was from. Between days 10 and 31 post UV-B irradiation, the average eye disease score was significantly higher in the HSV-1-infected group compared to the uninfected control group. These results were also similar to those previously reported (Morris et al. 2012a ), indicating that the UV-B model was working as expected.
UV-B irradiation induces more virus reactivation (shedding) in mice latently infected with wild-type LAT (+) virus compared to the LAT (−) virus dLAT2903 It is well established that in rabbits, the HSV-1 LAT plays an important role in both the in vivo spontaneous and induced reactivation phenotypes. Similarly, LAT plays an important role in induced reactivation of HSV-1 in the mouse TG explant-induced model and in the mouse heat-stressed model. However, some LAT mutants do not behave similarly in the in vivo rabbit model and the ex vivo mouse TG explant model (Loutsch et al. 1999; Maggioncalda et al. 1994) . It was therefore of interest to determine if LAT plays a significant role in the in vivo UV-B reactivation model in mice.
We therefore infected both eyes of 15 mice per group with either wild-type McKrae (LAT (+) virus) or dLAT2903 (LAT (−) virus), which was derived from McKrae. All procedures were as described above. Following UV-B irradiation, virus reactivation (shedding in tears) was determined and analyzed as in significantly greater than LAT (−) virus by both analyses. The results for the percent of virus-positive cultures (induced reactivation) seen from days 3 to 7 after UV-B irradiation are reminiscent of the percent of virus-positive tear cultures seen in rabbits from days 31 to 56 postinfection (spontaneous reactivation) (Perng et al. 1994) . Thus, the UV-B-induced reactivation mouse model readily distinguishes between LAT (+) and LAT (−) viruses and provides an additional model for determining the reactivation phenotype of HSV-1 mutants.
Discussion
Previous studies have used the UV-B mouse model of induced HSV-1 reactivation to investigate the protective efficacy of vaccines and drugs (e.g., acyclovir) and to determine the underlying immune mechanisms that protect from or promote recurrent HSK (Keadle et al. , 1997 (Keadle et al. , 2002a (Keadle et al. , 2002b (Keadle et al. , 2005 (Keadle et al. , 2002c (Keadle et al. , 2001 (Keadle et al. , 2000 Laycock et al. 1991; Morris et al. 2012a; Stuart and Keadle 2012a; Stuart et al. 2008; Walker et al. 1998 ). To our knowledge the effect of the HSV-1 LAT gene has not previously been investigated in the UV-B model.
LAT is both an indicator of HSV-1 latency and a critical gene in the latency/reactivation life cycle of HSV-1 (Hill et al. 1990; Leib et al. 1989; Perng et al. 1994; Rock et al. 1987; Spivack and Fraser 1987; Stevens et al. 1987; Trousdale et al. 1991) . Unlike other HSV-1 genes whose expression is tightly regulated in a cascade fashion of gene expression (i.e., α, β, and γ genes), LAT is expressed at all times. The LAT promoter functions in the absence of any other HSV-1 gene (Zwaagstra et al. 1989; Zwaagstra et al. 1990) , and LAT can be detected in tissue culture almost immediately after infection (Spivack and Fraser 1988a; Spivack and Fraser 1988b) . LAT expression remains on and LAT RNA accumulates such that at late times after tissue culture infection LAT is abundant. During latency in animal models and in humans, LAT is the only viral gene that is consistently and abundantly detected (Deatly et al. 1987; Rock et al. 1987; Stevens et al. 1987) . A low level of lytic cycle gene expression that is sometimes detected in ganglia during latent infection of mice (Feldman et al. 2002) is likely due to a small number of neurons undergoing abortive reactivation. Detection of lytic cycle gene expression in rabbits and in humans is likely due to viral reactivation in a small subset of neurons since spontaneous reactivation occurs in rabbits and humans.
LAT has anti-apoptosis activity (Perng et al. 2000) and can also act as an immune evasion gene (Allen et al. 2011; Allen et al. 2014; Chentoufi et al. 2012; Chentoufi et al. 2011; Jiang et al. 2011; Peng et al. 2005 ). Both of these LAT functions likely play a role in how LAT enhances the reactivation phenotype. Mouse models that require either the induction of reactivation or the detection of reactivation to take place ex vivo cannot fully take into account effects of LAT's immune evasion activity on HSV-1 reactivation and recurrent disease. The rabbit model of HSV-1 latency/reactivation appears to more closely resemble the human situation, since both spontaneous reactivation and induced reactivation take place completely in vivo. Unfortunately, because of limited availability of rabbit immunological reagents, and knock-in and knock-out rabbits, the ability to study the underlying cellular and molecular immune mechanisms in rabbits does not approach the robustness of such studies in mice. Thus, a fully in vivo reactivation model in the mouse in which the influence of LAT on the reactivation phenotype can be investigated would be a valuable asset for deciphering the cellular and molecular immune mechanisms that regulate HSV-1 latency/reactivation.
Most adults carry latent HSV-1, shed reactivated virus frequently, but remain asymptomatic having no recurrent disease (Kumar et al. 2009; Schacker et al. 1998; Wald et al. 1995) . In contrast, a small proportion of individuals is symptomatic and has frequent recurrent disease (Kumar et al. 2009; Schacker et al. 1998; Wald et al. 1995) . Cross talk between the immune system and the virus orchestrates HSV latency/reactivation (Allen et al. 2011; Allen et al. 2014; Chentoufi et al. 2012 ; Fig. 3 Recurrent eye disease following UV-B irradiation. The eyes from the experiment 1 shown in Fig. 2 were monitored for eye disease (clouding on a scale of 0 to 4 (Morris et al. 2012a )) on days 10, 17, and 31 post UV-B irradiation. Groups: wt McKrae, 15 eyes; control, naïve age-matched mice receiving the same UV-B irradiation treatment, 20 eyes. Double asterisk indicates highly significant differences on that day with a P value <0.001 as determined by a two-sided Fisher exact test Mice were ocularly infected as described in Materials and methods and the legend of Fig. 4 with LAT (+) (wild-type McKrae) virus (the parental virus for dLAT2903) or LAT (−) (dLAT2903) virus. Reactivation was induced by UV-B irradiation as described in Materials and methods Chentoufi et al. 2011; Ghiasi et al. 1992; Jiang et al. 2011; Peng et al. 2005) . Although most herpetic disease is due to viral reactivation, rather than to primary acute infection (Nesburn 1983; Nesburn et al. 1998a; Nesburn et al. 1998b) , the vast majority of experimental models investigating the immune mechanisms that orchestrate recurrent herpes disease have used the mouse model of primary acute infection, instead of more relevant models of recurrent disease (Morris et al. 2012b; Stuart and Keadle 2012a; Webre et al. 2012) . The extrapolation to human recurrent disease is uncertain, because the protective and pathological mechanisms that operate during primary herpetic disease are, in most part, different from those that operate during recurrent herpetic disease (Morris et al. 2012a; Stuart and Keadle 2012a; West et al. 2014 ). The UV-B model of HSV-1-induced reactivation is more likely to immunologically and pathologically mimic human recurrent ocular herpetic disease (Morris et al. 2012a; Stuart and Keadle 2012a; Webre et al. 2012) .
In addition to explant cultivation of TG and UV-B irradiation of eyes, other methods have also been used to induce reactivation of HSV-1 in mice. These include hyperthermia, sodium butyrate, cyclophosphamide plus dexamethasone, cadmium, cellophane, xylene, retinoic acid, iontophoresis of epinephrine, dimethyl sulfoxide, and physical restraint (Blyth et al. 1980; Cook et al. 1991; Halford et al. 1996; Harbour et al. 1981; Higaki et al. 2003; Higaki et al. 2002; Hill et al. 1982; Himmelein et al. 2011; Neumann et al. 2007; Sawtell and Thompson 1992; Toma et al. 2008; Zlotnik et al. 1970) . In these models, HSV-1 reactivation was assessed either by the presence of infectious virus in the ganglia in vitro or shedding of virus in tears. Shimeld et al. (1989 Shimeld et al. ( , 1990 ) compared immunosuppressive drugs (cyclophosphamide plus dexamethasone) to UV-B irradiation. Both induced HSV-1 reactivation judged by shedding of virus in tears, but only UV-B induced recurrent eye disease. To our knowledge, only UV-B has been reported to induce significant recurrent HSK, making it the most useful mouse model for investigating the cellular and molecular immunological mechanisms involved in recurrent herpetic eye disease. The UV-B method used in the present study was developed by Shimeld et al. (1989 Shimeld et al. ( , 1990 Shimeld et al. ( , 1996a Shimeld et al. ( , 1995 Shimeld et al. ( , 1996b Shimeld et al. ( , 1997 ) and adopted and modified by Laycock et al. (1994 , 1993 ) Pepose et al. (1992 , Stuart and Keadle (2012b) , and Morris et al. (2012a) . The present study extends the UV-B model by showing that LAT (+) (wt HSV-1) has a higher frequency of reactivation in this model than does LAT (−) HSV-1. It should be noted that the UV-B-induced reactivation model is not limited to C57BL/6 mice. With the NIH strain of mice UV-B-induced reactivation is 70-90 % as determined by detection of infectious virus in tear films (Keadle et al. 1997; Laycock et al. 1991; Stuart et al. 2004 ). UV-B successfully induced HSV-1 reactivation in latently infected Bhumanized^HLA transgenic mice generated on either a C57BL/6 or a BALB/c genetic background (not shown).
In the studies reported here, the recently described detailed procedures for the UV-B mouse model of HSV-1 reactivation (Morris et al. 2012a ) were followed as closely as possible. We found that UV-B irradiation of the eyes of latently infected mice induced reactivation of the LAT (+) virus more efficiently than it induced reactivation of the LAT (−) virus, as judged by detection of infectious virus in tears between days 3 and 7 post UV-B. The ability of LAT to enhance the reactivation phenotype in the in vivo UV-B-induced reactivation model was similar to the ability of LAT to enhance reactivation in other mouse models and in rabbits. In addition, the sensitivity of the UV-B mouse model to distinguish between LAT (+) and LAT (−) viruses was highly reminiscent of the rabbit model. Specifically, the percent of reactivated virus-positive cultures between days 3 and 7 post UV-B irradiation was 9 % for LAT (+) virus and 3 % for LAT (−) virus. This decreased reactivation with LAT (−) virus to approximately 33 % that of LAT (+) virus is similar to what is seen for spontaneous reactivation in latently infected rabbits (Perng et al. 1994 ). In our lab, this decreased spontaneous reactivation rate of LAT (-) viruses in the rabbit model is very consistent, while in the mouse TG explant model the difference between LAT (+) and LAT (-) viruses is sometimes not as clear cut. Published results for at least one LAT mutant also suggest that the in vivo rabbit model may be more sensitive in detecting HSV-1 mutational effects on the reactivation phenotype than ex vivo mouse models (Loutsch et al. 1999; Maggioncalda et al. 1996) . For these and other reasons discussed above, we feel that this fully in vivo mouse UV-B-induced reactivation model of HSV-1 should be a highly useful addition to deciphering the mechanism(s) by Fig. 4 UV-B -induced reactivation of LAT (+) versus LAT (−) virus. Fifteen mice/group (30 eyes) were infected, subjected to UV-B irradiation 30 days p.i. and induced reactivation analyzed as described in the legend of Fig. 2 . P values were determined by two-sided Fisher exact test which LAT enhances the reactivation phenotype and for investigating the cellular and molecular immune mechanisms involved in HSV-1 reactivation in general.
Every year, approximately 20,000 individuals in the USA develop symptoms of recurrent, painful, and potentially blinding ocular herpetic disease due to sporadic spontaneous reactivation of HSV-1 from latently infected sensory neurons of the TG (Kumar et al. 2009; Schacker et al. 1998; Wald et al. 1995) . To date, there is no licensed therapeutic vaccine that can effectively stop or reduce HSV-1 reactivation from latency. Current long-term anti-viral drug therapies (e.g., Acyclovir and derivatives) reduce recurrent ocular disease in symptomatic individuals by only ∼40 % and do not eliminate virus reactivation (HEDS 1998) . Identifying the cellular and molecular immune mechanisms that lead to HSV-1 reactivation from latently infected sensory neurons, the root of recurrent disease would help in developing more effective immunotherapies to prevent or reduce viral shedding in tears and, hence, reduce recurrent herpetic disease and blindness (reviewed in Kuo et al. 2014 ). The protective efficacy of candidate therapeutic vaccines and drugs against ocular herpes must first be preclinically tested in reliable animal models of recurrent ocular herpetic disease. We have found that the UV-B in vivo model of HSV-1-induced reactivation also works in our BhumanizedĤ LA-A*0201 transgenic mouse model of ocular herpes (not shown). This will allow us in future studies to test the therapeutic efficacy of candidate vaccines based on human HLA-A*0201-restricted CD8+ T cell epitopes (Khan et al. 2015) .
In conclusion, there are two principal findings in this report: (i) we successfully reproduced the UV-B model of HSV-1-induced reactivation and (ii) we found that HSV-1 reactivation induced by UV-B in the mouse model was increased in the presence of LAT.
